The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy

The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy

Although several programmed cell death (PD)-1 inhibitors are approved for the first-line treatment of advanced urothelial carcinoma, their efficacy remains unknown in cisplatin-ineligible patients with upper tract urothelial carcinoma (UTUC) compared with gemcitabine plus carboplatin. Data for patie...

Full description

Bibliographic Details
Main Authors: Jiwei Huang, Ruopeng Su, Zeyu Chen, Shuai Jiang, Minfeng Chen, Yichu Yuan, Hailong Hu, Changde Fu, Zhiyang Huang, Zhenyu Wang, Bing Zheng, Chancan Li, Zaoyu Wang, Yige Bao, Ming Cai, Jianming Guo, Qiang Wei, Wei Xue
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
Upper tract urothelial carcinoma
PD-1 inhibitor
carboplatin
Cisplatin-ineligible
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2124691

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2124691

Similar Items